Serial Circulating Tumor DNA (ctDNA) Analysis of Blood and Saliva Predicts Osimertinib Response and Resistance in EGFR-Mutant NSCLC

被引：0

作者：

Kim, C. ^{[1
]}

Xi, L. ^{[2
]}

Cultraro, C. ^{[1
]}

Wei, F. ^{[3
]}

Cheng, J. ^{[3
]}

Shafiei, A. ^{[4
]}

Pham, T. ^{[2
]}

Roper, N. ^{[1
]}

Akoth, E. ^{[1
]}

Strom, C. ^{[3
]}

Tu, M. ^{[5
]}

Liao, W. ^{[5
]}

Chia, D. ^{[3
]}

Morris, C. ^{[6
]}

Rajan, A. ^{[1
]}

Bagheri, M. ^{[4
]}

Jones, G. ^{[6
]}

Wong, D. ^{[3
]}

Raffeld, M. ^{[2
]}

Guha, U. ^{[1
]}

机构：

[1] NCI, Thorac & Gi Malignancies Branch, Ccr, NIH, Bethesda, MD 20892 USA

[2] NCI, Pathol Lab, Ccr, NIH, Bldg 10, Bethesda, MD 20892 USA

[3] Univ Calif Los Angeles, Los Angeles, CA USA

[4] NIH, Radiol & Imaging Sci, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA

[5] Ezlife Bio Inc, Woodlind Hills, CA USA

[6] Inivata, Cambridge, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期

关键词：

EGFR-mutant NSCLC; cDNA; Osimertinib;

D O I：

10.1016/j.jtho.2019.08.742

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.01-27

引用

页码：S366 / S366

页数：1

共 50 条

[41] Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer
Kok, Peey-Sei
Lee, Kirsty
Lord, Sally
John, Thomas
Marschner, Ian
Wu, Yi-Long
Mok, Tony S. K.
Lee, Chen Khoon
LUNG CANCER, 2022, 163 : 14 - 18
[42] ctDNA analysis identifies clinically meaningful resistance mutations in EGFR mutated NSCLC on osimertinib: a case report
Hack, Joanna
Bayne, Mike
LUNG CANCER, 2022, 165 : S74 - S75
[43] INSIGHT2: Tepotinib plus osimertinib in pts with EGFR-mutant NSCLC and acquired resistance to 1L osimertinib due to METamp
Morise, Masahiro
Sakai, Hiroshi
Kato, Terufumi
Tokito, Takaaki
Takeda, Masayuki
Tanaka, Hiroshi
Chikamori, Kenichi
Daga, Haruko
Kijima, Takashi
Ohashi, Kadoaki
Karachaliou, Niki
Ellers-Lenz, Barbara
Wu, Yi-Long
ANNALS OF ONCOLOGY, 2021, 32 : S309 - S309
[44] Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
Wang, Kaiwen
Du, Robyn
Roy-Chowdhuri, Sinchita
Li, Ziping T.
Hong, Lingzhi
Vokes, Natalie
Elamin, Yasir Y.
Hume, Celyne Bueno
Skoulidis, Ferdinandos
Gay, Carl M.
Blumenschein, George
Fossella, Frank V.
Tsao, Anne
Zhang, Jianjun
Karachaliou, Niki
O'Brate, Aurora
Gann, Claudia-Nanette
Lewis, Jeff
Rinsurongkawong, Waree
Lee, J. Jack
Gibbons, Don Lynn
Vaporciyan, Ara A.
Heymach, John V.
Altan, Mehmet
Le, Xiuning
JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (08):
[45] ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC
Caterina De Rosa
Viviana De Rosa
Concetta Tuccillo
Virginia Tirino
Luisa Amato
Federica Papaccio
Davide Ciardiello
Stefania Napolitano
Giulia Martini
Fortunato Ciardiello
Floriana Morgillo
Francesca Iommelli
Carminia Maria Della Corte
Scientific Reports, 14
[46] ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC
De Rosa, Caterina
De Rosa, Viviana
Tuccillo, Concetta
Tirino, Virginia
Amato, Luisa
Papaccio, Federica
Ciardiello, Davide
Napolitano, Stefania
Martini, Giulia
Ciardiello, Fortunato
Morgillo, Floriana
Iommelli, Francesca
Della Corte, Carminia Maria
SCIENTIFIC REPORTS, 2024, 14 (01)
[47] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
Kim, T. M.
Guarneri, V.
Jye, V. P.
Khaw, L. B.
Yang, J. -J.
Wislez, M.
Huang, C.
Kin, L. Chong
Mazieres, J.
Tho, L. M.
Hayashi, H.
Nhung, N.
Chia, P. L.
De Marinis, F.
Raskin, J.
Zhou, Q.
Finochhiaro, G.
Le, X.
Tan, D.
Brutlach, S.
O'Brate, A.
Adrian, S.
Berghoff, K.
Ellers-Lenz, B.
Karachaliou, N.
Wu, Y. -L.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S94 - S94
[48] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
Kim, Tae Min
Guarneri, Valentina
Voon, Pei Jye
Lim, Boon Khaw
Yang, Jin-ji
Wislez, Marie
Huang, Cheng
Liam, Chong Kin
Mazieres, Julien
Tho, Ye Mun
Hayashi, Hidetoshi
Nhung Nguyen
Chia, Puey Ling
de Marinis, Filippo
Raskin, Jo
Zhou, Qinghua
Finocchiaro, Giovanna
Le, Xiuning
Tan, Daniel
O'Hara, Richard M., Jr.
Brutlach, Sabine
O'Brate, Aurora
Adrian, Svenja
Berghoff, Karin
Ellers-Lenz, Barbara
Karachaliou, Niki
Wu, Yi-Long
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E38 - E38
[49] Tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis
Le, Xiuning
Kim, Tae Min
Guarneri, Valentina
Voon, Pei Jye
Lim, Boon Khaw
Yang, Jinji
Wislez, Marie
Huang, Cheng
Liam, Chong Kim
Mazieres, Julien
Lye Mun Tho
Hayashi, Hidetoshi
Nguyen Nhung
Chia, Puey Ling
De Marinis, Fillippo
Raskin, Jo
Zhou, Qinghua
Finochhiaro, Giovanna
Tan, Daniel
Brutlach, Sabine
O'Brate, Aurora
Adrian, Svenja
Berghoff, Karin
Ellers-Lenz, Barbara
Karachaliou, Niki
Wu, Yi-Long
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[50] Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings
Attili, Ilaria
Corvaja, Carla
Spitaleri, Gianluca
Aliaga, Pamela Trillo
Del Signore, Ester
Passaro, Antonio
de Marinis, Filippo
CANCERS, 2024, 16 (14)

← 1 2 3 4 5 →